Aspargo Laboratories, Inc. — Form D
Aspargo Laboratories, Inc. of ENGLEWOOD CLIFFS, NJ, a company, filed a Form D exempt-offering notice with the SEC on 2022-12-05. The offering totals $15.0M, of which $290K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-12-05
- Form: D
- Accession: 0001753926-22-001525
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $15.0M
- Amount sold: $290K
- Remaining: $14.7M
- Minimum investment: $40K
- Date of first sale: 2022-11-28
- Security types: equity
- Revenue range: $1 - $1,000,000
- SEC file number: 021-466492
Issuer
- Name: Aspargo Laboratories, Inc.
- CIK: 0001805092
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 550 SYLVAN AVENUE, ENGLEWOOD CLIFFS, NJ, 07632
- Phone: 2014084831
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Fred Biehl | Director | Short Hills, NJ |
| Michael Rice | Director | Bothell, WA |
| Michael Demurjian | Executive Officer | Red Bank, NJ |
| Michael Demurjian | Director | Red Bank, NJ |
| Michael Demurjian | Promoter | Red Bank, NJ |
Other filings by this issuer (4)
More